Literature DB >> 31693758

Using post-column infused internal standard assisted quantitative metabolomics for establishing prediction models for breast cancer detection.

Marisa Huang1, Hung-Yuan Li2, Hsiao-Wei Liao1,3, Ching-Hung Lin4,5, Chin-Yi Wang1, Wen-Hung Kuo6, Ching-Hua Kuo1,2,7.   

Abstract

RATIONALE: Breast cancer is one of the most common cancers among women and its associated mortality is on the rise. Metabolomics is a potential strategy for breast cancer detection. The post-column infused internal standard (PCI-IS)-assisted liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been demonstrated as an effective strategy for quantitative metabolomics. In this study, we evaluated the performance of targeted metabolomics with the PCI-IS quantification method to identify women with breast cancer.
METHODS: We used metabolite profiling to identify 17 dysregulated metabolites in breast cancer patients. Two LC/MS/MS methods in combination with the PCI-IS strategy were developed to quantify these metabolites in plasma samples. Detection models were built through the analysis of plasma samples from 176 subjects consisting of healthy volunteers and breast cancer patients.
RESULTS: Three isotope standards were selected as the PCI-ISs for the metabolites. The accuracy was within 82.8-114.16%, except for citric acid and lactic acid at high concentration levels. The repeatability and intermediate precision were all lower than 15% relative standard deviation. We have identified several metabolites that indicate the presence of breast cancer. The area under the receiver operating characteristics (AUROC) curve, sensitivity and specificity of the linear combinations of metabolite concentrations and age with the highest AUROC were 0.940 (0.889-0.992), 88.4% and 94.2% for pre-menopausal woman, respectively, and 0.828 (0.734-0.922), 73.5% and 85.1% for post-menopausal women, respectively.
CONCLUSIONS: The targeted metabolomics with PCI-IS quantification method successfully established prediction models for breast cancer detection. Further study is essential to validate these proposed markers.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Year:  2020        PMID: 31693758     DOI: 10.1002/rcm.8581

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  3 in total

1.  Multiplatform Investigation of Plasma and Tissue Lipid Signatures of Breast Cancer Using Mass Spectrometry Tools.

Authors:  Alex Ap Rosini Silva; Marcella R Cardoso; Luciana Montes Rezende; John Q Lin; Fernando Guimaraes; Geisilene R Paiva Silva; Michael Murgu; Denise Gonçalves Priolli; Marcos N Eberlin; Alessandra Tata; Livia S Eberlin; Sophie F M Derchain; Andreia M Porcari
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

Review 2.  The Function and Mechanism of Lipid Molecules and Their Roles in The Diagnosis and Prognosis of Breast Cancer.

Authors:  Rui Guo; Yu Chen; Heather Borgard; Mayumi Jijiwa; Masaki Nasu; Min He; Youping Deng
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

Review 3.  Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases.

Authors:  Adewale Victor Aderemi; Ademola Olabode Ayeleso; Oluboade Oluokun Oyedapo; Emmanuel Mukwevho
Journal:  Metabolites       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.